The Fight to Treat COVID: Sorting through therapeutics, from anti-virals to anti-inflammatories

The Fight to Treat COVID: Sorting through therapeutics, from anti-virals to anti-inflammatories

Fighting CovidSince SARS-CoV-2 emerged in 2019, there’s been a frenzy of scientific research on many fronts to help us understand and deal with this virus.

You’ve probably heard the most about vaccines, by a long shot. That’s because vaccines prepare your body to deal with a pathogen it hasn’t encountered yet. A vaccine or vaccine series primes the immune system to fight the virus long after the vaccine itself has left the body, for months, years, or a lifetime. The benefits are in the bank before you even get exposed. That makes vaccines an amazing tool.

What are the limits of vaccines? Well, it takes time to develop an immune response to a vaccine or booster, so it’s best to act before you see a surge of cases in your area—and certainly before you’re directly exposed. Meanwhile, the virus is evolving to produce more breakthrough infections. Though milder, these still sometimes require treatment. Vaccinated or not, millions of people are still getting COVID, so we definitely need additional tools to deal with this virus.

Antivirals: timing is everything

One primary research focus has been on antiviral medicine. Antivirals interfere with a virus by blocking some stage in its replication cycle. They might block it from attaching to a cell, block the cell from assembling pieces of a virus, or block the new viruses from leaving the cell. In an acute illness like COVID, you need to get antivirals into the system during the narrow window when the virus is multiplying quickly for them to help. Unfortunately, a lot of that window has passed when symptoms begin.

As an example many people are familiar with, Tamiflu is an antiviral drug used to treat the flu. Physicians would quickly put you on it if you have the flu, but the data showed you have to start taking it quickly after developing symptoms, and it would only shorten the duration of being sick by half a day to one day. That’s because, even after you stop the virus from multiplying, your body still has to fight it off.

Same conundrum with COVID. The idea behind antivirals is that by decreasing the peak viral load or stopping ongoing replication after the peak, we reduce the chances of a damaging cytokine storm and ramp down inflammation more quickly, which reduces accumulating damage to the lungs and body. But the antivirals that have been developed so far cause a number of side effects and have drug interactions with other medications. That makes using them difficult and not an ideal drug to treat large numbers of people.

In other words, despite the news hype, antivirals are not something the masses will use for COVID. They’re not as useful in reducing mild to moderate symptoms, and their side effect profile causes us to reserve their use for the most high-risk patients. In my opinion, the inflammatory response, which is just kicking into gear as symptoms begin, is really what we want to modulate.

Steroids: for rare and serious cases

In a previous post [LINK TO LAST COLUMN] I addressed immune-suppressing steroids for COVID. Their drawback is that you need your immune system working hard to fight the virus, so steroids can prolong the infection or open the door to secondary bacterial infections. Steroids need to be used with delicate caution when the immune system is already making progress against the virus. Even then, they are risky, so we use them when the severity of the situation warrants the risk. Unfortunately, this is when COVID has already progressed and caused damage.

Anti-inflammatories: a go-to for the general public

Finally, we have our anti-inflammatory drugs, including NSAIDS—non-steroidal antiinflammatories—and antihistamines. Many of these drugs, which have already been cleared as safe, can be very effective at calming certain, very reactive parts of the immune system while leaving other parts free to work. That means anti-inflammatories can be offered to more people with less risk than other post-exposure strategies. We can explore their ability to reduce mild to moderate symptoms as well as the frequency of progression to severe cases. I’m also interested in their ability to prevent long COVID symptoms from occurring, as we explore the relationship between long COVID and inflammation in the brain.

For most of this pandemic, the focus of research has been on the efficacy of vaccines and the possibility of antiviral drugs to treat breakthrough and unvaccinated COVID cases. In six months, I believe the focus will be on anti-inflammatories, and whether they can hone the immune response to do less collateral damage from COVID and even reduce the virus itself.

Thanks for reading.

Jackie Iversen, RPh, MS, Founder and Head of Clinical Development Sen-Jam Pharmaceutical
Check us out on WeFunder

Jacqueline Iversen